Doha, Zinab O.
Wang, Xiaoyan
Calistri, Nicholas L. http://orcid.org/0000-0002-8541-0919
Eng, Jennifer http://orcid.org/0000-0003-1499-8417
Daniel, Colin J.
Ternes, Luke
Kim, Eun Na
Pelz, Carl
Munks, Michael
Betts, Courtney
Kwon, Sunjong
Bucher, Elmar
Li, Xi
Waugh, Trent
Tatarova, Zuzana
Blumberg, Dylan
Ko, Aaron
Kirchberger, Nell
Pietenpol, Jennifer A.
Sanders, Melinda E.
Langer, Ellen M. http://orcid.org/0000-0003-0352-1859
Dai, Mu-Shui http://orcid.org/0000-0001-9031-6962
Mills, Gordon http://orcid.org/0000-0002-0144-9614
Chin, Koei http://orcid.org/0000-0001-8061-7462
Chang, Young Hwan http://orcid.org/0000-0001-8764-1959
Coussens, Lisa M. http://orcid.org/0000-0003-2389-1865
Gray, Joe W. http://orcid.org/0000-0001-9225-6756
Heiser, Laura M. http://orcid.org/0000-0003-3330-0950
Sears, Rosalie C. http://orcid.org/0000-0003-1558-2413
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA209988)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (BC201701)
Article History
Received: 2 December 2022
Accepted: 14 August 2023
First Online: 13 September 2023
Competing interests
: Declaration of interests: Rosalie C. Sears: Consultant: Novartis Pharmaceutical, Larkspur Biosciences. Scientific Advisory Board: RAPPTA Therapeutics. Sponsored Research Support: Cardiff Oncology, Astra Zeneca Partner of Choice grant award. Gordon Mills: SAB/Consultant: Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals. Stock/Options/Financial: Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, Turbine, Licensed Technology, HRD assay to Myriad Genetics, DSP patents with Nanostring. Sponsored research: AstraZeneca, Nanostring Center of Excellence, Ionis (Provision of tool compounds. The title and ID number for patents; Nanostring Simultaneous quantification of gene expression in a user-defined region of 10,640,816 a cross-sectioned tissue, Simultaneous quantification of a plurality of proteins in a user-defined region of 10,501,777 a cross-sectioned tissue, Myriad Methods and materials for assessing loss of heterozygosity 10,612,098. Lisa M. Coussens reports consulting services for Cell Signaling Technologies, AbbVie, the Susan G Komen Foundation, and Shasqi, received reagent and/or research support from Cell Signaling Technologies, Syndax Pharmaceuticals, ZelBio Inc., Hibercell Inc., and Acerta Pharma, and has participated in advisory boards for Pharmacyclics, Syndax, Carisma, Verseau, CytomX, Kineta, Hibercell, Cell Signaling Technologies, Alkermes, Zymeworks, Genenta Sciences, Pio Therapeutics Pty Ltd., PDX Pharmaceuticals, the AstraZeneca Partner of Choice Network, the Lustgarten Foundation, and the NIH/NCI-Frederick National Laboratory Advisory Committee. The remaining authors declare no competing interests.